Protalix Plans NDA Filing for Gaucher’s Drug This Year

Drug Industry Daily
A A
Less than a month after the FDA sought a treatment protocol for the Protalix Gaucher’s disease treatment, the company confirmed the clinical, nonclinical and chemistry requirements for its NDA with the agency and plans to file the application by year’s end.

To View This Article:

Login

Subscribe To Drug Industry Daily